The 2026 fantasy football season is already generating buzz as analysts scramble to pinpoint the most valuable running back options, especially those who can anchor a lineup as a true RB1.
Quinshon Judkins, the Cleveland Browns' starting running back, has secured the position despite a crowded backfield in 2025, and his workload suggests he will again serve as the team's primary ball‑carrier.
In 2025 Judkins rushed for 827 yards and seven touchdowns across 14 games, but his production was uneven, highlighted by a 237‑yard explosion early in the season followed by just 69 yards in the final three contests.
The Browns' quarterback situation adds another layer of uncertainty, as Deshaun Watson showed promise during preseason but the team remains unsure about long‑term stability at the helm.
Should Cleveland fall behind, the coaching staff may turn to RB2 Dylan Sampson, whose receiving skill set is considered weaker than Judkins', potentially reducing the veteran's snap count in high‑scoring games.
The Workhorse vs. The Injury‑Prone Prospect
Cam Skattebo of the New York Giants enters the conversation with a high ceiling‑to‑floor gap that stems from a serious ACL injury sustained in 2026, a setback that could reshape his fantasy outlook.
Last season Skattebo was utilized heavily as a pass‑catching back, recording two or more receptions in seven of eight games, but the emergence of two other RBs behind him on the depth chart threatens to shrink that role.
Preseason reports indicate Skattebo managed four carries for 19 yards, preserving his hard‑nosed running style from 2025, yet the presence of Devin Singletary and Tyrone Tracy Jr. ahead of him raises questions about his share of touches.
The combination of injury history, depth‑chart competition, and a potentially volatile Giants offense makes Skattebo a riskier proposition compared to Judkins, who offers a more predictable workload and a proven track record as a workhorse.
Consequently, fantasy analysts currently favor Judkins as the safer RB1 option for 2026, while Skattebo remains a high‑upside, high‑risk candidate whose value hinges on health and opportunity.